恒瑞医药：国家药监局核准签发关于 HRS-7172 片的《药物临床试验批准通知书》

Core Viewpoint - Heng Rui Medicine (600276)(01276) has received approval from the National Medical Products Administration for clinical trials of HRS-7172 tablets, a new anti-tumor small molecule inhibitor developed by the company [1] Group 1: Product Development - HRS-7172 tablets are a novel anti-tumor small molecule inhibitor independently developed by the company [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for the HRS-7172 project has reached approximately 28.41 million yuan [1]